The trial will evaluate the effects of low doses of psilocybin on combating demoralization in broader populations.

Research funding to UAB from the National Institutes of Health tops $300 million again.

The clinical trial focused on very young children, who have a more rapid loss of the pancreatic beta cells than do adolescents. The trial was constrained to a low-dose level, but showed safety and tolerability and reduced serum glucagon, a secondary outcome.